Virtual-Ports Ltd is thrilled to announce the attainment of CE certification under the new MDR for its groundbreaking surgical products. Renowned for their single-hand, multi-application design, Virtual-Ports' solutions are set to revolutionize abdominal surgery by significantly improving visibility and access within the surgical space.
Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform.
Apotex Corp. announced Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide® in the United States .Cetrorelix Acetate for Injection is a synthetic decapeptide with gonadotrophin-releasing hormone (GnRH) antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
"This launch provides American women access to affordable fertility treatments," said Christine Baeder, President, Apotex Corp. "It demonstrates our unwavering focus on meeting patient needs with high-quality medication that is more accessible to everyone."
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Magnesium Sulfate in Water for Injection in the United States as approved by the U.S.
Orthofix Medical Inc. a leading global spine and orthopedics company, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Rodeo™ Telescopic Nail.
SN Bioscience Co. Ltd. announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101 was designated as an orphan drug for small cell lung cancer and pancreatic cancer in July of last year and February of this year, respectively. By receiving fast-track designation this time, it is evaluated that it has laid the groundwork that can be commercialized immediately after completion of phase 2 clinical trials.
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.
Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to conduct the single-arm pivotal study for registration and market.
Axion BioSystems announced new Maestro Volt™, an affordable benchtop microelectrode array (MEA) system designed to meet the demands of academic labs with lower throughput needs and limited budgets.
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection (Eptifibatide) approved by the U.S. Food and Drug Administration.